

Rachelle Gordon is a cannabis and psychedelics writer dedicated to educating the masses on the powers of plant medicine. She is especially interested in the potential these compounds have with regard to the treatment of neurological disorders. A graduate of Hamline University in Saint Paul, Rachelle currently splits her time between Minneapolis and Oakland. Her favorite cultivars include Tangie, GMO, and Lemon Haze.



Nohtal Partansky is the founder and CEO of Sorting Robotics. He is a serial entrepreneur and former NASA-JPL engineer. At NASA-JPL, Nohtal was a cognizant engineer on the MOXIE project, an instrument currently on the surface of Mars producing oxygen from the Martian atmosphere. After leaving NASA-JPL, Nohtal founded Sorting Robotics with his two co-founders, Cassio Dos Santos Jr. and Sean Lawlor. Sorting Robotics builds innovative, AI-driven equipment for cannabis manufacturers and vertically integrated brands.



Davina Kaonohi is the CEO & co-founder of Element
Apothec. As a strategic leader and brand creator, Kaonohi is passionate about challenging the norm and making a difference with every company she has worked with. She is driven by a desire to truly make a difference both professionally and personally.



Alex Rogers is the founder and CEO of the International Cannabis Business Conference, which offers world-class industry networking as well as investment and capital opportunities. The International Cannabis Business Conference has upcoming events in Barcelona and Berlin. Visit internationalcbc.com to learn more.



Tami Kamin Meyer is an Ohio-based attorney and freelance writer. A dedicated kayaker and dog lover, her byline has appeared in Forbes, MarketWatch, Better Homes and Gardens, and Business. com. She is in her second stint as a member of the Board of Editors of the Columbus Bar Association and served as marketing/communications chair of the American Society of Journalists and Authors from 2018-2021. She tweets as @girlwithapen.



Deena Vallina is the CEO of Bud Counters and a Dope CFO VIP Cannabis Accountant trained in the cannabis industry. Bud Counters is headquartered in Las Vegas and serves the cannabis industry Nationwide. Deena serves on the Board of Directors of The Chamber of Cannabis, a 501(c)(3) organization based in Las Vegas, promoting cannabis legislation and advocacy.



Sarah Lee Gossett Parrish maintains a cannabis business law practice in Oklahoma. She is also admitted to practice in Texas and Colorado (single client). She has achieved Martindale-Hubbell's highest AV rating for peer and judicial review, and is one of The Cannabis Law Report's Global Top 200 Cannabis Legal Professionals. A member of the International Cannabis Bar Association and the National Cannabis Industry Association, Sarah Lee is a National Law Journal 2019 Cannabis Trailblazer. Learn more at www.slgparrishlaw.com.



David Wallach is an awardwinning writer, television producer, podcast host, marketing executive, fan of anything outdoors, and bacon lover. To see more of his work, check out www. davidwallach.net.



Zach Zerr is the director of product development for Bloom Distribution. He also writes about cannabis and hemp with a focus on consumer education.

Expanding Medical Cannabis Research

By Sarah Lee Gossett Parrish, Cannabis Business Attorney

A new year encourages hope and reflection, both of which are useful in evaluating existing cannabis policies at the federal level and what may be expected in the coming months. Significantly, while the industry suffered a loss in the unsuccessful efforts to include the Secure and Fair Enforcement (SAFE) Banking Act in the National Defense Authorization Act, Congress did pass the first standalone piece of cannabis reform legislation, the Medical Marijuana and Cannabidiol Research Expansion Act (H.R. 8454), which President Biden signed into law on Dec. 2, 2022. However, the legislation has met with mixed reviews among industry professionals, and whether it ultimately benefits medical cannabis research endeavors or serves as an impediment to them remains to be seen.

How Will H.R. 8454 Change Cannabis Research?

The bipartisan Medical Marijuana and Cannabidiol Research Expansion Act (H.R. 8454) eases federal restrictions on scientific research by streamlining the application process for approval of cannabis-related studies and simplifies requests for large quantities of cannabis for such studies. Currently, the United States Drug Enforcement Administration (DEA) reviews and licenses marijuana cultivators and grants Schedule I licenses to scientists seeking to study cannabis in clinical environments. The act changes this process by mandating that the United States Attorney General solicit cannabis cultivation applications for research or potential drug development purposes, and imposes a 60-day deadline for approval of research applications. Theoretically, these changes will eliminate the DEA's current lag times for approval of research protocols advanced by scientists working with cannabis, which have


been known to drag on for years.

Additionally, the act encourages the Food and Drug Administration to support cannabis-derived medications and requires federal agencies to provide a report concerning the "potential therapeutic effects of cannabidiol or marijuana on serious medical conditions." The act also directs the Department of Health and Human Services to work with the National Institutes of Health to analyze the therapeutic effects of cannabis for epilepsy and other conditions. Further, it will study how cannabis affects adolescent brain development, how it may impact the ability to operate motor vehicles, and determine how to overcome barriers that currently exist which inhibit cannabis research.

Who Grows the Research Crops?

One notable barrier to scientific research concerning the therapeutic benefits of cannabis that has existed for many years arises from current restrictions on the set of federally licensed cannabis cultivators. At present, this pool is limited to the University of Mississippi, which was granted a federal cannabis cultivation license in 1968. Unfortunately, the university has historically produced low-quality cannabis for research purposes, and the product's inferiority arguably has caused significant distortion in the results yielded from research projects utilizing such cannabis.

While the DEA expressed its intention to expand the pool of growers beyond the University of





Cannabis Science Relies on Quality Samples

It is undisputed that the quality of cannabis available for scientific research is of paramount importance. The language that would allow researchers to conduct studies on cannabis currently sold in state-legal markets, thereby aligning the quality of cannabis utilized in human clinical trials with the cannabis currently consumed by patients and adult consumers in state-legal markets, was removed before the act's passage by the Senate.

Paul Armentano, deputy director of the National Organization for the Reform of Marijuana Laws, criticized this omission, opining that "[w]hile the Expansion Act is a step in the right direction, the limited variety of cannabis cultivars accessible to federally licensed researchers does not represent the type or quality of cannabis products currently available in legal, statewide markets ... The fact that nearly one-half of U.S. adults have legal access to these multitudes of cannabis products, but our nation's top scientists do not, is the height of absurdity and highlights the need for continued legislative action if we want to more easily study the state-legal products that millions of Americans are actually using."

A Counterproductive Nightmare?

Armentano's astute observation highlights the disconnect that exists between current federal cannabis policies and the cannabis policies

adopted by states with medical and adult use legal markets. Oregon Democratic Representative Earl Blumenauer, co-sponsor of the legislation in the House with Maryland Republican Representative Andy Harris, commented in a statement that "[a]s we have seen in state after state, the public is tired of waiting for the federal government to catch up. More than 155 million Americans — nearly half of our nation's population — now reside in states where adult use of cannabis is legal."

Indeed, Blumenauer, founder and co-chair of the Congressional Cannabis Caucus, has worked on cannabis reform for decades. He further observed in his statement addressing the act's passage, "finally the dam is starting to break. The passage of my Medical Marijuana and Cannabidiol Research Expansion Act in the House and Senate represents a[n] historic breakthrough in addressing the federal government's failed and misguided prohibition of cannabis."

Nonetheless, the legislation is not without its critics, and perhaps for good reasons. Vicente Sederberg attorney Shane Pennington has dubbed it "a counterproductive nightmare," observing that the Act imposes DEA

registration requirements concerning CBD, whereas current law does not require any special DEA registration for CBD research. In an article titled Turning Water Into Weed And Other Absurdities, Pennington concludes that "[b]y imposing registration requirements on these otherwise-non-controlled substances, this bill dramatically increases barriers to cannabis research." (Emphasis original).

Shifting Cannabis Policy

Pennington observes that, via the attorney general, the DEA will have "unbridled authority to avoid licensing any marijuana manufacturers at all simply by refusing to place a notice in the federal register seeking more applications."

Currently, the Drug Enforcement

Administration does not have such power over any application.

Pennington also points out that the legislation provides the DEA with the ability to avoid deadline triggers simply by refusing to accept an application as "complete," in contrast to current DEA regulations under which the electronic filing system deems all applications received to be automatically complete or sends an error message advising of missing information necessary for resubmission.

Private research concerning the therapeutic benefits of cannabis is coming into its own.

Recently, the Wana Brands Foundation, led by founder and chief executive officer Nancy
Whiteman, awarded a \$3 million grant to Johns
Hopkins University to help further medical cannabis research. It will be interesting to follow the quality of cannabis available and actually utilized for such research, in light of the Medical Marijuana and Cannabidiol Research Expansion
Act. One can only hope that Congress will continue on a trajectory that promotes and encourages significant shifts in federal cannabis policies in this new year. Only time will tell.

SPOTLIGHT: NEW ENGLAND TURNS OVER A NEW LEAF | PAR EXCELLENCE AT LEMONHAZE GOLF INVITATIONAL

DEEPAK CHOPRA

IFINITE OTENTIAL

Psychedelics, Neuralink, and Cannabis as a Holy Experience

Health & Wellness Issue



East Coast Tribe Heats Up the Hamptons

Gearing Up

for Cannabis in the NFL

Cannabis Gets Sexy: Taking It to the Sheets

Top 20

Must-Have Products



SINCE LAST ISSUE...



Cannabis & Tech Today is buzzing from a recent brick-and-mortar expansion.

Innovative Properties Worldwide (IPW), the parent company of Cannabis & Tech Today, Innovation & Tech Today, Residential Tech Today, STEM Today, and Sustainability Today, opened the doors on its new location in downtown Denver, CO in Dec. 2022. IPW is onboarding several new staff members and looking forward to continued growth throughout 2023.



Welcome Aboard!

In addition to new staff in the sales and editorial departments, IPW welcomed Chief Operating Officer Ashley Manning to the administrative team. Manning brings years of experience and high-level connections from the cannabis industry to her role as COO. With Manning on board, IPW can offer our readers more inspiring insights than ever before.

Calling on Content Creators Cannabis & Tech Today is now accepting applications for internship opportunities. Reach out to submit@innotechtoday.com if you're interested in joining our team of award-winning content creators. This publication is entering its fifth year in print and your voice could help speak to a new generation of cannabis connoisseurs. Earn college credit, gain valuable experience, and share your passion by joining a motivated team of journalists.

SPECIAL THANKS TO:

The American Civil Liberties Union, NORML, Christian York, James Miller, Edna Dolan, Helen Freed, Tom Dolan, Randy Wilson, Nicole Widmer

This publication is dedicated to the dreamers, the innovators, the collaborators, and the doers – who can't be bothered by those saying it can't be done. Nicholas and Aria, the future is *yours!*



Scan to Subscribe Today!

For print or digital subscriptions, visit cannatechtoday.com, or find us on popular digital newsstands and readers.











A PREMIUM QUARTERLY CELEBRATING THE SCIENCE AND TECH OF THE CANNABIS BUSINESS

cannabis tech

PUBLISHER/EDITOR-IN-CHIEF

Charles Warner cwarner@goipw.com

CREATIVE DIRECTOR

Shane Brisson

STEETHE BITTEOTO

shane@goipw.com

MANAGING EDITOR

Patricia Miller

ASSOCIATE EDITOR
SENIOR WRITERS

Aron Vaughan Ebby Stone

CONTRIBUTING WRITERS

Hal Bishop Rachelle Gordon Davina Kaonohi Tami Kamin Meyer Sarah Lee Gossett Parrish

Nohtal Partansky Alex Rogers David Wallach Deena Vallina Zach Zerr

CHIEF OPERATING OFFICER Ashle

CHIEF FINANCIAL OFFICER

Ashley Manning

DIRECTOR OF SALES

Mary Roche

SALES & PRODUCTION MANAGER

Steven Higgins Surge Ali

ACCOUNT EXECUTIVES

Marcus Culhane Rachielle Gillstrap

Chris Howell
Thomas Johnston

EXECUTIVE ASSISTANT

Tatiana Allensworth

VIDEO/PODCAST PRODUCER

Alan Tuszynski

SENIOR DIRECTOR, DEVELOPMENT

David Marble

DISTRIBUTION

CMG

PRINTING

Publication Printers

Cannabis & Tech Today is part of the PrintReleaf program helping to sustain and grow our global forestry system.



printreleaf

Published by:
INNOVATIVE PROPERTIES WORLDWIDE, INC
3461 Ringsby Ct. #245
Denver CO 80216 | (720) 476-4920
www.cannatechtoday.com | info@cannatechtoday.com



公司(0)

TAL

To learn more about unique advertising opportunities, please contact Steven Higgins at 727-771-5998.

Follow. 1 Like. Share. Win. @CannaTechToday

CANNABIS & TECH TODAY -

Vol. 4/Issue 4, is published quarterly for \$19.95 per year by Innovative Properties Worldwide, 3461 Ringsby Ct. #245, Denver CO 80216



POSTMASTER: Send address changes to CANNABIS & TECH TODAY, 3461 Ringsby Ct. #245, Denver CO 80216

All trademarks, service marks, photos, and logos contained within this publication are the property of their respective owners, and may not be individually identified in this publication.